No need for financial disclosure at Avastin hearing, officer says

06/20/2011 | San Francisco Chronicle

Karen Midthun, who will preside over a public hearing on Genentech's cancer drug Avastin next week, rejected an FDA proposal that would require witnesses to disclose financial relationships with the drug’s maker or competitors. Roche, Genentech's parent, is appealing the agency's plan to revoke Avastin's approval for breast cancer. The FDA may cross-examine witnesses if it "is concerned that there are additional financial interests that affect the credibility of the opinions advanced by the Genentech presenters," Midthun said.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA